Global Vasomotor Symptoms Treatment Market Research Report 2025(Status and Outlook)

March 2025 | 185 pages | ID: GC2A6A40BB00EN
Bosson Research

Abstracts

Report Overview

Vasomotor symptoms treatment refers to the various methods and medications used to alleviate symptoms such as hot flashes and night sweats that are commonly experienced during menopause. These treatments aim to regulate hormonal imbalances and manage the physiological changes that occur during this stage in a woman's life. The market for vasomotor symptoms treatment includes pharmaceutical products, herbal remedies, hormone therapy, and lifestyle interventions. With the increasing awareness and acceptance of menopausal symptoms as a medical condition, the demand for effective treatment options is on the rise. As women seek ways to improve their quality of life and manage uncomfortable symptoms, the market for vasomotor symptoms treatment continues to expand.

Market trends indicate a growing preference for natural and alternative remedies among women experiencing vasomotor symptoms. This shift towards herbal supplements, acupuncture, and lifestyle changes is driven by concerns over the potential risks associated with hormone therapy and pharmaceutical interventions. In addition, technological advancements in the healthcare industry have led to the development of innovative treatment options such as wearable devices and mobile applications that help women track and manage their symptoms more effectively. The market is also influenced by factors such as changing demographics, increasing healthcare expenditure, and a greater focus on women's health issues. As a result, the vasomotor symptoms treatment market is expected to witness steady growth in the coming years, with opportunities for new entrants to introduce novel solutions catering to the evolving needs of menopausal women.

This report provides a deep insight into the global Vasomotor Symptoms Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Vasomotor Symptoms Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Vasomotor Symptoms Treatment market in any manner.

Global Vasomotor Symptoms Treatment Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bayer AG

Fervent Pharmaceuticals

LLC

Astellas Pharma Inc.

Frazier Healthcare Partners

Mitsubishi Tanabe Pharma Corporation

Eli Lilly and Company

AbbVie Inc.

AMAG Pharmaceuticals Inc.

Emcure Pharmaceuticals Limited

Merck & Co.

Inc.

Novartis AG

Novo Nordisk A/S

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Market Segmentation (by Type)

Hormonal Therapies

Non-Hormonal Therapies

Others

Market Segmentation (by Application)

Clinic

Hospital

Others

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Vasomotor Symptoms Treatment Market
• Overview of the regional outlook of the Vasomotor Symptoms Treatment Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Vasomotor Symptoms Treatment Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Vasomotor Symptoms Treatment
1.2 Key Market Segments
  1.2.1 Vasomotor Symptoms Treatment Segment by Type
  1.2.2 Vasomotor Symptoms Treatment Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 VASOMOTOR SYMPTOMS TREATMENT MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Vasomotor Symptoms Treatment Market Size (M USD) Estimates and Forecasts (2020-2033)
  2.1.2 Global Vasomotor Symptoms Treatment Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 VASOMOTOR SYMPTOMS TREATMENT MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Vasomotor Symptoms Treatment Product Life Cycle
3.3 Global Vasomotor Symptoms Treatment Sales by Manufacturers (2020-2025)
3.4 Global Vasomotor Symptoms Treatment Revenue Market Share by Manufacturers (2020-2025)
3.5 Vasomotor Symptoms Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Vasomotor Symptoms Treatment Average Price by Manufacturers (2020-2025)
3.7 Manufacturers Vasomotor Symptoms Treatment Manufacturing Sites, Area Served, Product Type
3.8 Vasomotor Symptoms Treatment Market Competitive Situation and Trends
  3.8.1 Vasomotor Symptoms Treatment Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Vasomotor Symptoms Treatment Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 VASOMOTOR SYMPTOMS TREATMENT INDUSTRY CHAIN ANALYSIS

4.1 Vasomotor Symptoms Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF VASOMOTOR SYMPTOMS TREATMENT MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Vasomotor Symptoms Treatment Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 Global Trade Frictions and Their Impacts to Vasomotor Symptoms Treatment Market
5.7 ESG Ratings of Leading Companies

6 VASOMOTOR SYMPTOMS TREATMENT MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Vasomotor Symptoms Treatment Sales Market Share by Type (2020-2025)
6.3 Global Vasomotor Symptoms Treatment Market Size Market Share by Type (2020-2025)
6.4 Global Vasomotor Symptoms Treatment Price by Type (2020-2025)

7 VASOMOTOR SYMPTOMS TREATMENT MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Vasomotor Symptoms Treatment Market Sales by Application (2020-2025)
7.3 Global Vasomotor Symptoms Treatment Market Size (M USD) by Application (2020-2025)
7.4 Global Vasomotor Symptoms Treatment Sales Growth Rate by Application (2020-2025)

8 VASOMOTOR SYMPTOMS TREATMENT MARKET SALES BY REGION

8.1 Global Vasomotor Symptoms Treatment Sales by Region
  8.1.1 Global Vasomotor Symptoms Treatment Sales by Region
  8.1.2 Global Vasomotor Symptoms Treatment Sales Market Share by Region
8.2 Global Vasomotor Symptoms Treatment Market Size by Region
  8.2.1 Global Vasomotor Symptoms Treatment Market Size by Region
  8.2.2 Global Vasomotor Symptoms Treatment Market Size Market Share by Region
8.3 North America
  8.3.1 North America Vasomotor Symptoms Treatment Sales by Country
  8.3.2 North America Vasomotor Symptoms Treatment Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Vasomotor Symptoms Treatment Sales by Country
  8.4.2 Europe Vasomotor Symptoms Treatment Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Vasomotor Symptoms Treatment Sales by Region
  8.5.2 Asia Pacific Vasomotor Symptoms Treatment Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Vasomotor Symptoms Treatment Sales by Country
  8.6.2 South America Vasomotor Symptoms Treatment Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Vasomotor Symptoms Treatment Sales by Region
  8.7.2 Middle East and Africa Vasomotor Symptoms Treatment Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 VASOMOTOR SYMPTOMS TREATMENT MARKET PRODUCTION BY REGION

9.1 Global Production of Vasomotor Symptoms Treatment by Region(2020-2025)
9.2 Global Vasomotor Symptoms Treatment Revenue Market Share by Region (2020-2025)
9.3 Global Vasomotor Symptoms Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Vasomotor Symptoms Treatment Production
  9.4.1 North America Vasomotor Symptoms Treatment Production Growth Rate (2020-2025)
  9.4.2 North America Vasomotor Symptoms Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Vasomotor Symptoms Treatment Production
  9.5.1 Europe Vasomotor Symptoms Treatment Production Growth Rate (2020-2025)
  9.5.2 Europe Vasomotor Symptoms Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Vasomotor Symptoms Treatment Production (2020-2025)
  9.6.1 Japan Vasomotor Symptoms Treatment Production Growth Rate (2020-2025)
  9.6.2 Japan Vasomotor Symptoms Treatment Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Vasomotor Symptoms Treatment Production (2020-2025)
  9.7.1 China Vasomotor Symptoms Treatment Production Growth Rate (2020-2025)
  9.7.2 China Vasomotor Symptoms Treatment Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Bayer AG
  10.1.1 Bayer AG Basic Information
  10.1.2 Bayer AG Vasomotor Symptoms Treatment Product Overview
  10.1.3 Bayer AG Vasomotor Symptoms Treatment Product Market Performance
  10.1.4 Bayer AG Business Overview
  10.1.5 Bayer AG SWOT Analysis
  10.1.6 Bayer AG Recent Developments
10.2 Fervent Pharmaceuticals
  10.2.1 Fervent Pharmaceuticals Basic Information
  10.2.2 Fervent Pharmaceuticals Vasomotor Symptoms Treatment Product Overview
  10.2.3 Fervent Pharmaceuticals Vasomotor Symptoms Treatment Product Market Performance
  10.2.4 Fervent Pharmaceuticals Business Overview
  10.2.5 Fervent Pharmaceuticals SWOT Analysis
  10.2.6 Fervent Pharmaceuticals Recent Developments
10.3 LLC
  10.3.1 LLC Basic Information
  10.3.2 LLC Vasomotor Symptoms Treatment Product Overview
  10.3.3 LLC Vasomotor Symptoms Treatment Product Market Performance
  10.3.4 LLC Business Overview
  10.3.5 LLC SWOT Analysis
  10.3.6 LLC Recent Developments
10.4 Astellas Pharma Inc.
  10.4.1 Astellas Pharma Inc. Basic Information
  10.4.2 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Overview
  10.4.3 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Market Performance
  10.4.4 Astellas Pharma Inc. Business Overview
  10.4.5 Astellas Pharma Inc. Recent Developments
10.5 Frazier Healthcare Partners
  10.5.1 Frazier Healthcare Partners Basic Information
  10.5.2 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Overview
  10.5.3 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Market Performance
  10.5.4 Frazier Healthcare Partners Business Overview
  10.5.5 Frazier Healthcare Partners Recent Developments
10.6 Mitsubishi Tanabe Pharma Corporation
  10.6.1 Mitsubishi Tanabe Pharma Corporation Basic Information
  10.6.2 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product Overview
  10.6.3 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product Market Performance
  10.6.4 Mitsubishi Tanabe Pharma Corporation Business Overview
  10.6.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
10.7 Eli Lilly and Company
  10.7.1 Eli Lilly and Company Basic Information
  10.7.2 Eli Lilly and Company Vasomotor Symptoms Treatment Product Overview
  10.7.3 Eli Lilly and Company Vasomotor Symptoms Treatment Product Market Performance
  10.7.4 Eli Lilly and Company Business Overview
  10.7.5 Eli Lilly and Company Recent Developments
10.8 AbbVie Inc.
  10.8.1 AbbVie Inc. Basic Information
  10.8.2 AbbVie Inc. Vasomotor Symptoms Treatment Product Overview
  10.8.3 AbbVie Inc. Vasomotor Symptoms Treatment Product Market Performance
  10.8.4 AbbVie Inc. Business Overview
  10.8.5 AbbVie Inc. Recent Developments
10.9 AMAG Pharmaceuticals Inc.
  10.9.1 AMAG Pharmaceuticals Inc. Basic Information
  10.9.2 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Overview
  10.9.3 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Market Performance
  10.9.4 AMAG Pharmaceuticals Inc. Business Overview
  10.9.5 AMAG Pharmaceuticals Inc. Recent Developments
10.10 Emcure Pharmaceuticals Limited
  10.10.1 Emcure Pharmaceuticals Limited Basic Information
  10.10.2 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Overview
  10.10.3 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Market Performance
  10.10.4 Emcure Pharmaceuticals Limited Business Overview
  10.10.5 Emcure Pharmaceuticals Limited Recent Developments
10.11 Merck and Co.
  10.11.1 Merck and Co. Basic Information
  10.11.2 Merck and Co. Vasomotor Symptoms Treatment Product Overview
  10.11.3 Merck and Co. Vasomotor Symptoms Treatment Product Market Performance
  10.11.4 Merck and Co. Business Overview
  10.11.5 Merck and Co. Recent Developments
10.12 Inc.
  10.12.1 Inc. Basic Information
  10.12.2 Inc. Vasomotor Symptoms Treatment Product Overview
  10.12.3 Inc. Vasomotor Symptoms Treatment Product Market Performance
  10.12.4 Inc. Business Overview
  10.12.5 Inc. Recent Developments
10.13 Novartis AG
  10.13.1 Novartis AG Basic Information
  10.13.2 Novartis AG Vasomotor Symptoms Treatment Product Overview
  10.13.3 Novartis AG Vasomotor Symptoms Treatment Product Market Performance
  10.13.4 Novartis AG Business Overview
  10.13.5 Novartis AG Recent Developments
10.14 Novo Nordisk A/S
  10.14.1 Novo Nordisk A/S Basic Information
  10.14.2 Novo Nordisk A/S Vasomotor Symptoms Treatment Product Overview
  10.14.3 Novo Nordisk A/S Vasomotor Symptoms Treatment Product Market Performance
  10.14.4 Novo Nordisk A/S Business Overview
  10.14.5 Novo Nordisk A/S Recent Developments
10.15 Pfizer Inc.
  10.15.1 Pfizer Inc. Basic Information
  10.15.2 Pfizer Inc. Vasomotor Symptoms Treatment Product Overview
  10.15.3 Pfizer Inc. Vasomotor Symptoms Treatment Product Market Performance
  10.15.4 Pfizer Inc. Business Overview
  10.15.5 Pfizer Inc. Recent Developments
10.16 Teva Pharmaceutical Industries Ltd.
  10.16.1 Teva Pharmaceutical Industries Ltd. Basic Information
  10.16.2 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Overview
  10.16.3 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Market Performance
  10.16.4 Teva Pharmaceutical Industries Ltd. Business Overview
  10.16.5 Teva Pharmaceutical Industries Ltd. Recent Developments

11 VASOMOTOR SYMPTOMS TREATMENT MARKET FORECAST BY REGION

11.1 Global Vasomotor Symptoms Treatment Market Size Forecast
11.2 Global Vasomotor Symptoms Treatment Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Vasomotor Symptoms Treatment Market Size Forecast by Country
  11.2.3 Asia Pacific Vasomotor Symptoms Treatment Market Size Forecast by Region
  11.2.4 South America Vasomotor Symptoms Treatment Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Vasomotor Symptoms Treatment by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

12.1 Global Vasomotor Symptoms Treatment Market Forecast by Type (2026-2033)
  12.1.1 Global Forecasted Sales of Vasomotor Symptoms Treatment by Type (2026-2033)
  12.1.2 Global Vasomotor Symptoms Treatment Market Size Forecast by Type (2026-2033)
  12.1.3 Global Forecasted Price of Vasomotor Symptoms Treatment by Type (2026-2033)
12.2 Global Vasomotor Symptoms Treatment Market Forecast by Application (2026-2033)
  12.2.1 Global Vasomotor Symptoms Treatment Sales (K Units) Forecast by Application
  12.2.2 Global Vasomotor Symptoms Treatment Market Size (M USD) Forecast by Application (2026-2033)

13 CONCLUSION AND KEY FINDINGS
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Vasomotor Symptoms Treatment Market Size Comparison by Region (M USD)
Table 5. Global Vasomotor Symptoms Treatment Sales (K Units) by Manufacturers (2020-2025)
Table 6. Global Vasomotor Symptoms Treatment Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Vasomotor Symptoms Treatment Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Vasomotor Symptoms Treatment Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasomotor Symptoms Treatment as of 2024)
Table 10. Global Market Vasomotor Symptoms Treatment Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 11. Manufacturers Vasomotor Symptoms Treatment Manufacturing Sites and Area Served
Table 12. Manufacturers Vasomotor Symptoms Treatment Product Type
Table 13. Global Vasomotor Symptoms Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Vasomotor Symptoms Treatment Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. Global Vasomotor Symptoms Treatment Sales by Type (K Units)
Table 25. Global Vasomotor Symptoms Treatment Market Size by Type (M USD)
Table 26. Global Vasomotor Symptoms Treatment Sales (K Units) by Type (2020-2025)
Table 27. Global Vasomotor Symptoms Treatment Sales Market Share by Type (2020-2025)
Table 28. Global Vasomotor Symptoms Treatment Market Size (M USD) by Type (2020-2025)
Table 29. Global Vasomotor Symptoms Treatment Market Size Share by Type (2020-2025)
Table 30. Global Vasomotor Symptoms Treatment Price (USD/Unit) by Type (2020-2025)
Table 31. Global Vasomotor Symptoms Treatment Sales (K Units) by Application
Table 32. Global Vasomotor Symptoms Treatment Market Size by Application
Table 33. Global Vasomotor Symptoms Treatment Sales by Application (2020-2025) & (K Units)
Table 34. Global Vasomotor Symptoms Treatment Sales Market Share by Application (2020-2025)
Table 35. Global Vasomotor Symptoms Treatment Market Size by Application (2020-2025) & (M USD)
Table 36. Global Vasomotor Symptoms Treatment Market Share by Application (2020-2025)
Table 37. Global Vasomotor Symptoms Treatment Sales Growth Rate by Application (2020-2025)
Table 38. Global Vasomotor Symptoms Treatment Sales by Region (2020-2025) & (K Units)
Table 39. Global Vasomotor Symptoms Treatment Sales Market Share by Region (2020-2025)
Table 40. Global Vasomotor Symptoms Treatment Market Size by Region (2020-2025) & (M USD)
Table 41. Global Vasomotor Symptoms Treatment Market Size Market Share by Region (2020-2025)
Table 42. North America Vasomotor Symptoms Treatment Sales by Country (2020-2025) & (K Units)
Table 43. North America Vasomotor Symptoms Treatment Market Size by Country (2020-2025) & (M USD)
Table 44. Europe Vasomotor Symptoms Treatment Sales by Country (2020-2025) & (K Units)
Table 45. Europe Vasomotor Symptoms Treatment Market Size by Country (2020-2025) & (M USD)
Table 46. Asia Pacific Vasomotor Symptoms Treatment Sales by Region (2020-2025) & (K Units)
Table 47. Asia Pacific Vasomotor Symptoms Treatment Market Size by Region (2020-2025) & (M USD)
Table 48. South America Vasomotor Symptoms Treatment Sales by Country (2020-2025) & (K Units)
Table 49. South America Vasomotor Symptoms Treatment Market Size by Country (2020-2025) & (M USD)
Table 50. Middle East and Africa Vasomotor Symptoms Treatment Sales by Region (2020-2025) & (K Units)
Table 51. Middle East and Africa Vasomotor Symptoms Treatment Market Size by Region (2020-2025) & (M USD)
Table 52. Global Vasomotor Symptoms Treatment Production (K Units) by Region(2020-2025)
Table 53. Global Vasomotor Symptoms Treatment Revenue (US$ Million) by Region (2020-2025)
Table 54. Global Vasomotor Symptoms Treatment Revenue Market Share by Region (2020-2025)
Table 55. Global Vasomotor Symptoms Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 56. North America Vasomotor Symptoms Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 57. Europe Vasomotor Symptoms Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 58. Japan Vasomotor Symptoms Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 59. China Vasomotor Symptoms Treatment Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Bayer AG Basic Information
Table 61. Bayer AG Vasomotor Symptoms Treatment Product Overview
Table 62. Bayer AG Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 63. Bayer AG Business Overview
Table 64. Bayer AG SWOT Analysis
Table 65. Bayer AG Recent Developments
Table 66. Fervent Pharmaceuticals Basic Information
Table 67. Fervent Pharmaceuticals Vasomotor Symptoms Treatment Product Overview
Table 68. Fervent Pharmaceuticals Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 69. Fervent Pharmaceuticals Business Overview
Table 70. Fervent Pharmaceuticals SWOT Analysis
Table 71. Fervent Pharmaceuticals Recent Developments
Table 72. LLC Basic Information
Table 73. LLC Vasomotor Symptoms Treatment Product Overview
Table 74. LLC Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. LLC Business Overview
Table 76. LLC SWOT Analysis
Table 77. LLC Recent Developments
Table 78. Astellas Pharma Inc. Basic Information
Table 79. Astellas Pharma Inc. Vasomotor Symptoms Treatment Product Overview
Table 80. Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Astellas Pharma Inc. Business Overview
Table 82. Astellas Pharma Inc. Recent Developments
Table 83. Frazier Healthcare Partners Basic Information
Table 84. Frazier Healthcare Partners Vasomotor Symptoms Treatment Product Overview
Table 85. Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Frazier Healthcare Partners Business Overview
Table 87. Frazier Healthcare Partners Recent Developments
Table 88. Mitsubishi Tanabe Pharma Corporation Basic Information
Table 89. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product Overview
Table 90. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Mitsubishi Tanabe Pharma Corporation Business Overview
Table 92. Mitsubishi Tanabe Pharma Corporation Recent Developments
Table 93. Eli Lilly and Company Basic Information
Table 94. Eli Lilly and Company Vasomotor Symptoms Treatment Product Overview
Table 95. Eli Lilly and Company Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Eli Lilly and Company Business Overview
Table 97. Eli Lilly and Company Recent Developments
Table 98. AbbVie Inc. Basic Information
Table 99. AbbVie Inc. Vasomotor Symptoms Treatment Product Overview
Table 100. AbbVie Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. AbbVie Inc. Business Overview
Table 102. AbbVie Inc. Recent Developments
Table 103. AMAG Pharmaceuticals Inc. Basic Information
Table 104. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product Overview
Table 105. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. AMAG Pharmaceuticals Inc. Business Overview
Table 107. AMAG Pharmaceuticals Inc. Recent Developments
Table 108. Emcure Pharmaceuticals Limited Basic Information
Table 109. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product Overview
Table 110. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Emcure Pharmaceuticals Limited Business Overview
Table 112. Emcure Pharmaceuticals Limited Recent Developments
Table 113. Merck and Co. Basic Information
Table 114. Merck and Co. Vasomotor Symptoms Treatment Product Overview
Table 115. Merck and Co. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Merck and Co. Business Overview
Table 117. Merck and Co. Recent Developments
Table 118. Inc. Basic Information
Table 119. Inc. Vasomotor Symptoms Treatment Product Overview
Table 120. Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Inc. Business Overview
Table 122. Inc. Recent Developments
Table 123. Novartis AG Basic Information
Table 124. Novartis AG Vasomotor Symptoms Treatment Product Overview
Table 125. Novartis AG Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126. Novartis AG Business Overview
Table 127. Novartis AG Recent Developments
Table 128. Novo Nordisk A/S Basic Information
Table 129. Novo Nordisk A/S Vasomotor Symptoms Treatment Product Overview
Table 130. Novo Nordisk A/S Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. Novo Nordisk A/S Business Overview
Table 132. Novo Nordisk A/S Recent Developments
Table 133. Pfizer Inc. Basic Information
Table 134. Pfizer Inc. Vasomotor Symptoms Treatment Product Overview
Table 135. Pfizer Inc. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 136. Pfizer Inc. Business Overview
Table 137. Pfizer Inc. Recent Developments
Table 138. Teva Pharmaceutical Industries Ltd. Basic Information
Table 139. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product Overview
Table 140. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 141. Teva Pharmaceutical Industries Ltd. Business Overview
Table 142. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 143. Global Vasomotor Symptoms Treatment Sales Forecast by Region (2026-2033) & (K Units)
Table 144. Global Vasomotor Symptoms Treatment Market Size Forecast by Region (2026-2033) & (M USD)
Table 145. North America Vasomotor Symptoms Treatment Sales Forecast by Country (2026-2033) & (K Units)
Table 146. North America Vasomotor Symptoms Treatment Market Size Forecast by Country (2026-2033) & (M USD)
Table 147. Europe Vasomotor Symptoms Treatment Sales Forecast by Country (2026-2033) & (K Units)
Table 148. Europe Vasomotor Symptoms Treatment Market Size Forecast by Country (2026-2033) & (M USD)
Table 149. Asia Pacific Vasomotor Symptoms Treatment Sales Forecast by Region (2026-2033) & (K Units)
Table 150. Asia Pacific Vasomotor Symptoms Treatment Market Size Forecast by Region (2026-2033) & (M USD)
Table 151. South America Vasomotor Symptoms Treatment Sales Forecast by Country (2026-2033) & (K Units)
Table 152. South America Vasomotor Symptoms Treatment Market Size Forecast by Country (2026-2033) & (M USD)
Table 153. Middle East and Africa Vasomotor Symptoms Treatment Sales Forecast by Country (2026-2033) & (Units)
Table 154. Middle East and Africa Vasomotor Symptoms Treatment Market Size Forecast by Country (2026-2033) & (M USD)
Table 155. Global Vasomotor Symptoms Treatment Sales Forecast by Type (2026-2033) & (K Units)
Table 156. Global Vasomotor Symptoms Treatment Market Size Forecast by Type (2026-2033) & (M USD)
Table 157. Global Vasomotor Symptoms Treatment Price Forecast by Type (2026-2033) & (USD/Unit)
Table 158. Global Vasomotor Symptoms Treatment Sales (K Units) Forecast by Application (2026-2033)
Table 159. Global Vasomotor Symptoms Treatment Market Size Forecast by Application (2026-2033) & (M USD)
List of Figures
Figure 1. Product Picture of Vasomotor Symptoms Treatment
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Vasomotor Symptoms Treatment Market Size (M USD), 2024-2033
Figure 5. Global Vasomotor Symptoms Treatment Market Size (M USD) (2020-2033)
Figure 6. Global Vasomotor Symptoms Treatment Sales (K Units) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Vasomotor Symptoms Treatment Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Vasomotor Symptoms Treatment Product Life Cycle
Figure 13. Vasomotor Symptoms Treatment Sales Share by Manufacturers in 2024
Figure 14. Global Vasomotor Symptoms Treatment Revenue Share by Manufacturers in 2024
Figure 15. Vasomotor Symptoms Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Vasomotor Symptoms Treatment Average Price (USD/Unit) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Vasomotor Symptoms Treatment Revenue in 2024
Figure 18. Industry Chain Map of Vasomotor Symptoms Treatment
Figure 19. Global Vasomotor Symptoms Treatment Market PEST Analysis
Figure 20. Global Vasomotor Symptoms Treatment Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Vasomotor Symptoms Treatment Market Share by Type
Figure 27. Sales Market Share of Vasomotor Symptoms Treatment by Type (2020-2025)
Figure 28. Sales Market Share of Vasomotor Symptoms Treatment by Type in 2024
Figure 29. Market Size Share of Vasomotor Symptoms Treatment by Type (2020-2025)
Figure 30. Market Size Share of Vasomotor Symptoms Treatment by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Vasomotor Symptoms Treatment Market Share by Application
Figure 33. Global Vasomotor Symptoms Treatment Sales Market Share by Application (2020-2025)
Figure 34. Global Vasomotor Symptoms Treatment Sales Market Share by Application in 2024
Figure 35. Global Vasomotor Symptoms Treatment Market Share by Application (2020-2025)
Figure 36. Global Vasomotor Symptoms Treatment Market Share by Application in 2024
Figure 37. Global Vasomotor Symptoms Treatment Sales Growth Rate by Application (2020-2025)
Figure 38. Global Vasomotor Symptoms Treatment Sales Market Share by Region (2020-2025)
Figure 39. Global Vasomotor Symptoms Treatment Market Size Market Share by Region (2020-2025)
Figure 40. North America Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 41. North America Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 42. North America Vasomotor Symptoms Treatment Sales Market Share by Country in 2024
Figure 43. North America Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Vasomotor Symptoms Treatment Market Size Market Share by Country in 2024
Figure 45. U.S. Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 46. U.S. Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Vasomotor Symptoms Treatment Sales (K Units) and Growth Rate (2020-2025)
Figure 48. Canada Vasomotor Symptoms Treatment Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Vasomotor Symptoms Treatment Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Vasomotor Symptoms Treatment Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 52. Europe Vasomotor Symptoms Treatment Sales Market Share by Country in 2024
Figure 53. Europe Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Vasomotor Symptoms Treatment Market Size Market Share by Country in 2024
Figure 55. Germany Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 56. Germany Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 58. France Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 60. U.K. Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. Italy Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Spain Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Vasomotor Symptoms Treatment Sales and Growth Rate (K Units)
Figure 66. Asia Pacific Vasomotor Symptoms Treatment Sales Market Share by Region in 2024
Figure 67. Asia Pacific Vasomotor Symptoms Treatment Market Size Market Share by Region in 2024
Figure 68. China Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 69. China Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 71. Japan Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 73. South Korea Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 75. India Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 77. Southeast Asia Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Vasomotor Symptoms Treatment Sales and Growth Rate (K Units)
Figure 79. South America Vasomotor Symptoms Treatment Sales Market Share by Country in 2024
Figure 80. South America Vasomotor Symptoms Treatment Market Size and Growth Rate (M USD)
Figure 81. South America Vasomotor Symptoms Treatment Market Size Market Share by Country in 2024
Figure 82. Brazil Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 83. Brazil Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 85. Argentina Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 87. Columbia Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Vasomotor Symptoms Treatment Sales and Growth Rate (K Units)
Figure 89. Middle East and Africa Vasomotor Symptoms Treatment Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Vasomotor Symptoms Treatment Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Vasomotor Symptoms Treatment Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 93. Saudi Arabia Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 95. UAE Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 97. Egypt Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 99. Nigeria Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Vasomotor Symptoms Treatment Sales and Growth Rate (2020-2025) & (K Units)
Figure 101. South Africa Vasomotor Symptoms Treatment Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Vasomotor Symptoms Treatment Production Market Share by Region (2020-2025)
Figure 103. North America Vasomotor Symptoms Treatment Production (K Units) Growth Rate (2020-2025)
Figure 104. Europe Vasomotor Symptoms Treatment Production (K Units) Growth Rate (2020-2025)
Figure 105. Japan Vasomotor Symptoms Treatment Production (K Units) Growth Rate (2020-2025)
Figure 106. China Vasomotor Symptoms Treatment Production (K Units) Growth Rate (2020-2025)
Figure 107. Global Vasomotor Symptoms Treatment Sales Forecast by Volume (2020-2033) & (K Units)
Figure 108. Global Vasomotor Symptoms Treatment Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Vasomotor Symptoms Treatment Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Vasomotor Symptoms Treatment Market Share Forecast by Type (2026-2033)
Figure 111. Global Vasomotor Symptoms Treatment Sales Forecast by Application (2026-2033)
Figure 112. Global Vasomotor Symptoms Treatment Market Share Forecast by Application (2026-2033)